New diabetes drug HRS9531 aims to improve blood sugar control in phase 3 trial
NCT ID NCT07060456
First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests if HRS9531 can lower blood sugar better than a placebo in people with type 2 diabetes who are already using basal insulin. About 300 adults will receive either HRS9531 or a placebo for 40 weeks. The main goal is to see if HRS9531 improves long-term blood sugar levels (HbA1c).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Perking University Peoples' Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact
Conditions
Explore the condition pages connected to this study.